ZA200600027B - Pharmaceutical formulations for intranasal administration of protein comprising a chitosan or a derivative thereof - Google Patents

Pharmaceutical formulations for intranasal administration of protein comprising a chitosan or a derivative thereof

Info

Publication number: ZA200600027B
Authority: ZA; South Africa
Prior art keywords: chitosan; derivative; protein; pharmaceutical formulations; intranasal administration
Prior art date: 2003-07-04

Application number

ZA200600027A

Other languages

English (en)

Inventor

Dyer Ann Margaret

Cheng Yu-Hui

Watts Peter James

Smith Alan

Original Assignee

Archimedes Dev Ltd

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2003-07-04

Filing date

2006-01-03

Publication date

2009-08-26

2006-01-03 Application filed by Archimedes Dev Ltd filed Critical Archimedes Dev Ltd

2009-08-26 Publication of ZA200600027B publication Critical patent/ZA200600027B/xx

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0043—Nose
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/27—Growth hormone [GH], i.e. somatotropin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Chemical & Material Sciences (AREA)
Animal Behavior & Ethology (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Public Health (AREA)
Endocrinology (AREA)
Epidemiology (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Otolaryngology (AREA)
Immunology (AREA)
Gastroenterology & Hepatology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Zoology (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Medicinal Preparation (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

ZA200600027A 2003-07-04 2006-01-03 Pharmaceutical formulations for intranasal administration of protein comprising a chitosan or a derivative thereof ZA200600027B (en)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
GBGB0315632.0A GB0315632D0 (en)	2003-07-04	2003-07-04	Pharmaceutical formulations

Publications (1)

Publication Number	Publication Date
ZA200600027B true ZA200600027B (en)	2009-08-26

Family

ID=27741549

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
ZA200600027A ZA200600027B (en)	2003-07-04	2006-01-03	Pharmaceutical formulations for intranasal administration of protein comprising a chitosan or a derivative thereof

Country Status (14)

Country	Link
US (2)	US7662403B2 (xx)
EP (1)	EP1641434B1 (xx)
AT (1)	ATE417599T1 (xx)
AU (1)	AU2004255515B2 (xx)
CA (1)	CA2531239C (xx)
DE (1)	DE602004018496D1 (xx)
DK (1)	DK1641434T3 (xx)
ES (1)	ES2319995T3 (xx)
GB (1)	GB0315632D0 (xx)
NZ (1)	NZ544718A (xx)
PL (1)	PL1641434T3 (xx)
PT (1)	PT1641434E (xx)
WO (1)	WO2005004838A1 (xx)
ZA (1)	ZA200600027B (xx)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB0315632D0 (en)	2003-07-04	2003-08-13	West Pharm Serv Drug Res Ltd	Pharmaceutical formulations
US20090136505A1 (en)	2005-02-23	2009-05-28	Johanna Bentz	Intranasal Administration of Active Agents to the Central Nervous System
GB2438834A (en)	2006-06-08	2007-12-12	Optinose As	Intranasal protein administration
CA2657581A1 (en) *	2006-07-11	2008-01-17	Roy C. Levitt	Rhinosinusitis prevention and therapy with proinflammatory cytokine inhibitors
US20080182819A1 (en) *	2007-01-29	2008-07-31	Act Iii Licensing, Llc	Chitosan compositions and methods for using chitosan compositions in the treatment of health disorders
GB0812742D0 (en)	2008-07-11	2008-08-20	Critical Pharmaceuticals Ltd	Process
WO2010056896A1 (en)	2008-11-12	2010-05-20	Synedgen, Inc.	Chitosan derivatives to treat animals or optimize animal health
US20140294977A1 (en) *	2011-11-23	2014-10-02	Durect Corporation	Radiation-Sterilized Biodegradable Drug Delivery Composition
GB201319437D0 (en) *	2013-11-04	2013-12-18	Nanomerics Ltd	Delivery of drugs
WO2015088990A1 (en)	2013-12-09	2015-06-18	Durect Corporation	Pharmaceutically active agent complexes, polymer complexes, and compositions and methods involving the same
DK3981414T3 (da)	2015-02-01	2025-07-14	Quetzal Therapeutics Llc	Lyofiliserede præparater med højt overfladeareal, der indeholder arsenik til oral indgivelse i patienter
EP3880233A1 (en)	2018-06-22	2021-09-22	Bioralix B.V.	Formulations of biological polymers for oral administration

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5690954A (en) *	1987-05-22	1997-11-25	Danbiosyst Uk Limited	Enhanced uptake drug delivery system having microspheres containing an active drug and a bioavailability improving material
GB8904370D0 (en)	1989-02-25	1989-04-12	Cosmas Damian Ltd	Liquid delivery compositions
JPH07118170A (ja) *	1993-10-19	1995-05-09	Dot:Kk	経鼻吸収薬物用キャリヤ、生理活性ペプチド組成物およびその製造法
US20010053359A1 (en) *	1994-07-26	2001-12-20	Peter Watts	Drug delivery composition for the nasal administration of antiviral agents
GB9416884D0 (en)	1994-08-20	1994-10-12	Danbiosyst Uk	Drug delivery compositions
GB9419979D0 (en)	1994-10-04	1994-11-16	Medeva Holdings Bv	Vaccine compositions
SE9403905D0 (sv) *	1994-11-14	1994-11-14	Astra Ab	New formulations
GB9522351D0 (en)	1995-11-01	1996-01-03	Medeva Holdings Bv	Vaccine compositions
GB9525083D0 (en) *	1995-12-07	1996-02-07	Danbiosyst Uk	Vaccine compositions
AU722319B2 (en)	1996-02-27	2000-07-27	Teijin Limited	Powdery composition for nasal administration
US5912014A (en) *	1996-03-15	1999-06-15	Unigene Laboratories, Inc.	Oral salmon calcitonin pharmaceutical products
DE69712110T2 (de)	1996-07-10	2002-12-12	West Pharmaceutical Services Drug Delivery & Clinical Research Centre Ltd., Nottingham	Zusammensetzungen zur einführung von genen in epithelzellen
GB9700624D0 (en) *	1997-01-14	1997-03-05	Danbiosyst Uk	Drug delivery composition
GB9707934D0 (en) *	1997-04-18	1997-06-04	Danbiosyst Uk	Improved delivery of drugs to mucosal surfaces
GB9713980D0 (en)	1997-07-03	1997-09-10	Danbiosyst Uk	New conjugates
GB9725084D0 (en)	1997-11-28	1998-01-28	Medeva Europ Ltd	Vaccine compositions
DE69930509T2 (de) *	1998-07-08	2006-11-30	Kirin-Amgen Inc., Wilmington	Pulverförmiges präparat zur anwendung auf schleimhäuten welches ein polymeres arzneimittel enthält
SE9803239D0 (sv)	1998-09-24	1998-09-24	Diabact Ab	Composition for the treatment of acute pain
GB9924797D0 (en) *	1999-10-20	1999-12-22	West Pharm Serv Drug Res Ltd	Compound
US20020013331A1 (en)	2000-06-26	2002-01-31	Williams Robert O.	Methods and compositions for treating pain of the mucous membrane
DE20122843U1 (de)	2000-07-31	2008-06-26	Nycomed Danmark Aps	Fentanyl Zusammensetzung zur nasalen Anwendung
JP2005518430A (ja) *	2001-11-19	2005-06-23	ベクトン・ディキンソン・アンド・カンパニー	微粒子形態の薬剤組成物
US7666876B2 (en)	2002-03-19	2010-02-23	Vernalis (R&D) Limited	Buprenorphine formulations for intranasal delivery
GB0300531D0 (en)	2003-01-10	2003-02-12	West Pharm Serv Drug Res Ltd	Pharmaceutical compositions
GB0315632D0 (en)	2003-07-04	2003-08-13	West Pharm Serv Drug Res Ltd	Pharmaceutical formulations

2003
- 2003-07-04 GB GBGB0315632.0A patent/GB0315632D0/en not_active Ceased
2004
- 2004-07-02 PT PT04743222T patent/PT1641434E/pt unknown
- 2004-07-02 DE DE602004018496T patent/DE602004018496D1/de not_active Expired - Lifetime
- 2004-07-02 AT AT04743222T patent/ATE417599T1/de active
- 2004-07-02 EP EP04743222A patent/EP1641434B1/en not_active Expired - Lifetime
- 2004-07-02 AU AU2004255515A patent/AU2004255515B2/en not_active Ceased
- 2004-07-02 NZ NZ544718A patent/NZ544718A/en not_active IP Right Cessation
- 2004-07-02 CA CA2531239A patent/CA2531239C/en not_active Expired - Fee Related
- 2004-07-02 DK DK04743222T patent/DK1641434T3/da active
- 2004-07-02 PL PL04743222T patent/PL1641434T3/pl unknown
- 2004-07-02 ES ES04743222T patent/ES2319995T3/es not_active Expired - Lifetime
- 2004-07-02 WO PCT/GB2004/002876 patent/WO2005004838A1/en not_active Ceased
2006
- 2006-01-03 ZA ZA200600027A patent/ZA200600027B/xx unknown
- 2006-01-04 US US11/325,073 patent/US7662403B2/en not_active Expired - Fee Related
2009
- 2009-09-30 US US12/570,039 patent/US8481070B2/en not_active Expired - Fee Related

Also Published As

Publication number	Publication date
US8481070B2 (en)	2013-07-09
GB0315632D0 (en)	2003-08-13
AU2004255515A1 (en)	2005-01-20
PL1641434T3 (pl)	2009-08-31
CA2531239A1 (en)	2005-01-20
US20100021553A1 (en)	2010-01-28
US7662403B2 (en)	2010-02-16
EP1641434B1 (en)	2008-12-17
PT1641434E (pt)	2009-03-19
NZ544718A (en)	2009-06-26
CA2531239C (en)	2011-05-24
DE602004018496D1 (de)	2009-01-29
WO2005004838A8 (en)	2005-03-17
EP1641434A1 (en)	2006-04-05
WO2005004838A1 (en)	2005-01-20
AU2004255515B2 (en)	2009-04-30
AU2004255515A2 (en)	2005-01-20
ATE417599T1 (de)	2009-01-15
ES2319995T3 (es)	2009-05-18
DK1641434T3 (da)	2009-04-06
US20060120973A1 (en)	2006-06-08

Publication	Publication Date	Title
WO2002092147A3 (en)	2003-11-27	Optimization of the molecular properties and formulation of proteins delivered by inhalation
YU26101A (sh)	2003-02-28	Oslobađanje aerosoliziranog aktivnog agensa modulisane otpornosti protoka
AU2003295614A1 (en)	2004-06-23	Delivery of pharmaceutical agents via the human insulin receptor
ZA200600027B (en)	2009-08-26	Pharmaceutical formulations for intranasal administration of protein comprising a chitosan or a derivative thereof
MXPA05010565A (es)	2005-11-23	Sistemas de suminsitro de farmacos que comprenden un ingrediente activo encapsulado.
EP2186507A3 (en)	2011-08-10	A liquid pharmaceutical formulation comprising nicotine for the administration to the oral cavity
WO2008021088A3 (en)	2008-12-24	Salicylanilides enhance oral delivery of therapeutic peptides
AU1200501A (en)	2001-04-23	Drug delivery catheters that attach to tissue and methods for their use
ITMI20020399A0 (it)	2002-02-28	Composizioni dietetiche e/o farmaceutiche per uso umano e/o animale abase di preparati microbici probiotici
AP1760A (en)	2007-07-18	Platinum derivative pharmaceutical formulations.
BG104720A (en)	2001-04-30	Aerosolized active agent delivery
AU2003239531A1 (en)	2003-12-02	Protein cages for the delivery of medical imaging and therapy
FR11C0017I2 (fr)	2012-06-15	Utilisation de spinosad ou d'une formulation comprennant spinosad
DK1499360T3 (da)	2009-02-09	Formulering omfattende buprenorphin
AU2003213675A1 (en)	2003-09-22	Controlled delivery patch of active ingredient
AU2001270300A1 (en)	2002-01-21	Drug delivery formulations and targeting
AU2003207016A1 (en)	2003-09-02	Pharmaceutical formulation for administration by inhalation comprising an androstane derivative and a beta-2-adrenoreceptor for the treatment of inflammatory and allergic conditions
DK1392254T3 (da)	2007-07-02	Micelle-lægemiddelindgivelsessystem for hydrofobe lægemidler
WO2003079993A3 (en)	2004-03-04	hGH (HUMAN GROWTH HORMONE) FORMULATIONS FOR PULMONARY ADMINISTRATION
GB9918559D0 (en)	1999-10-06	Novel pharmaceutical formulation
IL145069A0 (en)	2002-06-30	Pharmaceutical compositions for delivery to an external wall of a body passageway or cavity
EP1501497A4 (en)	2007-07-11	CATECHIN MULTIMES THAN THERAPEUTIC DRUGS SUBSTITUTES
WO2003007876A3 (en)	2009-09-17	N-fatty acid-amino acid conjugates and therapeutic uses
AU2002332836A1 (en)	2003-03-18	Stabilizing catheter for protein drug delivery
AU2273301A (en)	2001-07-09	Methods and formulations for the efficient delivery of water-insoluble drugs by nebulizer